Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX NASDAQ:TNGX NASDAQ:VKTX NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$38.83+6.4%$34.14$12.15▼$40.76$3.93B0.271.85 million shs1.03 million shsTNGXTango Therapeutics$28.39-0.4%$24.78$4.60▼$34.39$4.12B1.195.32 million shs5.39 million shsVKTXViking Therapeutics$34.81+7.5%$31.45$22.96▼$43.15$3.76B0.691.98 million shs6.21 million shsXNCRXencor$14.08+0.5%$12.18$6.92▼$18.69$1.04B0.92742,728 shs1.14 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+6.38%+14.37%+18.75%+21.57%+173.84%TNGXTango Therapeutics-0.39%-11.72%+40.27%+35.97%+433.65%VKTXViking Therapeutics+7.54%+17.40%+12.69%+4.85%+40.02%XNCRXencor+0.50%+15.41%+24.49%+13.55%+67.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$38.83+6.4%$34.14$12.15▼$40.76$3.93B0.271.85 million shs1.03 million shsTNGXTango Therapeutics$28.39-0.4%$24.78$4.60▼$34.39$4.12B1.195.32 million shs5.39 million shsVKTXViking Therapeutics$34.81+7.5%$31.45$22.96▼$43.15$3.76B0.691.98 million shs6.21 million shsXNCRXencor$14.08+0.5%$12.18$6.92▼$18.69$1.04B0.92742,728 shs1.14 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics+6.38%+14.37%+18.75%+21.57%+173.84%TNGXTango Therapeutics-0.39%-11.72%+40.27%+35.97%+433.65%VKTXViking Therapeutics+7.54%+17.40%+12.69%+4.85%+40.02%XNCRXencor+0.50%+15.41%+24.49%+13.55%+67.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.78Moderate Buy$47.3021.81% UpsideTNGXTango Therapeutics 2.71Moderate Buy$38.4235.32% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60168.89% UpsideXNCRXencor 2.40Hold$24.5074.01% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, TNGX, EWTX, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $59.006/17/2026EWTXEdgewise Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $32.006/16/2026EWTXEdgewise Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.006/16/2026EWTXEdgewise Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/12/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026TNGXTango Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $66.006/9/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $42.006/8/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetPeer Perform ➝ Outperform$35.006/8/2026TNGXTango Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026TNGXTango Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$55.00 ➝ $69.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ATNGXTango Therapeutics$62.38M65.83N/AN/A$2.57 per share11.05VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/AXNCRXencor$125.58M8.31N/AN/A$8.90 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest XNCR, TNGX, EWTX, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A22.6122.61TNGXTango TherapeuticsN/A27.3827.38VKTXViking TherapeuticsN/A5.725.72XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/ATNGXTango Therapeutics78.99%VKTXViking Therapeutics76.03%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics21.30%TNGXTango Therapeutics6.50%VKTXViking Therapeutics5.30%XNCRXencor5.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableXNCRXencor28074.14 million70.38 millionOptionableXNCR, TNGX, EWTX, and VKTX HeadlinesRecent News About These CompaniesXencor Updates Outlook Amid Ultomiris Royalty DisputeJune 19, 2026 | theglobeandmail.comXencor Shareholders Approve Directors, Incentive Plan AmendmentsJune 18, 2026 | tipranks.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Hold" from AnalystsJune 18, 2026 | americanbankingnews.comXencor (NASDAQ:XNCR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?June 17, 2026 | americanbankingnews.comXencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets CautionJune 15, 2026 | uk.finance.yahoo.comIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30, 2026 | seekingalpha.comJefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCRMay 25, 2026 | marketbeat.comXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comXencor: Q1 Earnings SnapshotMay 6, 2026 | ctpost.comCXencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comXencor Reports First Quarter 2026 Financial ResultsMay 6, 2026 | businesswire.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 TranscriptMay 5, 2026 | seekingalpha.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - SlideshowMay 5, 2026 | seekingalpha.comXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWMay 4, 2026 | businesswire.comJP Morgan Downgrades Xencor (XNCR)March 25, 2026 | msn.comXencor (XNCR) Receives a Buy from WedbushMarch 17, 2026 | theglobeandmail.comXencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptMarch 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXNCR, TNGX, EWTX, and VKTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$38.83 +2.33 (+6.38%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$38.37 -0.46 (-1.18%) As of 06/23/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Tango Therapeutics NASDAQ:TNGX$28.39 -0.11 (-0.39%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$28.40 +0.01 (+0.04%) As of 06/23/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$34.81 +2.44 (+7.54%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$34.89 +0.08 (+0.23%) As of 06/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$14.08 +0.07 (+0.50%) As of 06/23/2026 04:00 PM EasternXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
